BOSTON --(BUSINESS WIRE)--Aug. 26, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will
— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and development pipeline; povetacicept PDUFA date November 30th — — Entered into agreement to acquire
BOSTON --(BUSINESS WIRE)--Jul. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY ®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional children in the U.S. are now eligible for this established one-time therapy, expanding upon the prior FDA
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older - - Data simultaneously
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of
BOSTON --(BUSINESS WIRE)--Jun. 3, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on
- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA)
BOSTON --(BUSINESS WIRE)--May 11, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, will participate in a fireside chat at the 2026 RBC Capital Markets
-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany - BOSTON --(BUSINESS WIRE)--May 6, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the
– Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 – – Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for povetacicept in IgA nephropathy, following positive Phase 3 interim analysis data; initiated Phase
BOSTON --(BUSINESS WIRE)--Apr. 6, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET.
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein- -Approximately 800 more people with CF in the US are
- For the primary endpoint, patients treated with povetacicept achieved a 52.0% reduction from baseline in proteinuria as measured by 24-hour urine protein to creatinine ratio (UPCR) and achieved a statistically significant and clinically meaningful 49.8% reduction in UPCR versus placebo (P
BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a
-Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting - BOSTON --(BUSINESS WIRE)--Mar. 5, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: